Informasjon

Overgangsalderen

Overgangsalderen, klimakteriet, er i utgangspunktet en normal prosess og ingen sykdom. Symptomene skyldes at eggstokkene gradvis slutter å fungere rundt 50 års alder. Dette fører til bortfall av menstruasjon og varierende grader av symptomer på grunn av lavere østrogenmengde i kroppen.

Sist revidert: 14.03.2022

Hva er overgangsalderen?

Klimakteriet er et annet navn på overgangsalderen og omfatter perioden før og etter den siste menstruasjonsblødningen. Den siste menstruasjonsblødningen som markerer opphør av menstruasjonene, kalles menopausen. Menopausen inntrer vanligvis i 45 til 55 års alderen. Blant norske kvinner er det funnet at menopausen i gjennomsnitt inntrer ved 53 års alder. Klimakteriet starter noen år tidligere, og plagene varer ofte en del år både før og etter menopausen.

Animasjon om opphør av menstruasjon (menopausen)

Vil du vite mer?

Få tilgang på artikkelen om dette temaet fra Legehandboka.no

Artikkelen inneholder all informasjon norske allmennleger bruker i sitt daglige arbeid.

Jeg har lest og akseptert Brukervilkår ved kjøp av NEL-dokumenter

Dette dokumentet er basert på det profesjonelle dokumentet "Klimakteriet". Referanselisten for dette dokumentet vises nedenfor.

Øverlie I et al. Klimakteriet. Norsk gynekologisk forening Veileder i gynekologi (2021). ePub. ISBN 978-82-692382-1-1. Siden besøkt 25.04.2022 www.legeforeningen.no
Vujovic S, Brincat M, Erel T et al. EMAS position statement: Managing women with premature ovarian failure. Maturitas 2010;67:91-3. pmid: 20605383 PubMed
Gjelsvik B, Rosvold EO, Straand J, Dalen I, Hunskaar S. Symptom prevalence during menopause and factors associated with symptoms and menopausal age. Results from the Norwegian Hordaland Women's Cohort study. Maturitas, 2011; 70 (4): 383–390. pmid:10.1016/j.maturitas.2011.09.011
Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015. pmid: 25686030 PubMed
Kinney A, Kline J, Levin B. Alcohol, caffeine and smoking in relation to age at menopause. Maturitas. 2006;54:27-38. PMID: 16260101 PubMed
Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol. 2014 Oct;43(5):1542-62. Epub 2014 Apr 26. PMID: 24771324 PubMed
Duffy OK, Iversen L, Hannaford PC. Factors associated with reporting classic menopausal symptoms differ. Climacteric 2013; 16: 240-51. pmid:22992029 PubMed
Øverlie I, Moen MH, Holte A, Finset A. Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas. 2002 Jan 30;41(1):69-77. PMID: 11809345. PubMed
Legeforeningen. Gjør kloke valg. Anbefalinger. Siden besøkt 11.02.2021 www.legeforeningen.no
Norsk kvalitetsforbedring av laboratorieundersøkelser (Noklus). Anbefalte analyser ved utvalgte kliniske problemstillinger. Siden besøkt 01.10.2020 www.noklus.no
US Preventive Services Task Force Recommendation Statement. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women. JAMA 2017; 318: 2224-33. doi:10.1001/jama.2017.18261 DOI
Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310: 1353-68. pmid: 24084921 PubMed
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD004143. The Cochrane Library
Bassuk SS, Manson JE. The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolism. 2016 May;65(5):794-803. Epub 2016 Jan 12. PMID: 27085786 PubMed
Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012 Aug 15;8 pmid: 22895916 PubMed
Ockene JK, Barad DH, Cochrane BB et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA. 2005 Jul 13;294(2):183-93. PMID: 16014592.
Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD006108. pmid: 25431132 PubMed
Kemmler W, Häberle L, von Stengel S. Effects of exercise on fracture reduction in older adults : A systematic review and meta-analysis. Osteoporos Int. 2013 Jul:1937-50. pmid: 23306820 PubMed
Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016 Aug 31;(8):CD001500..CD001500.pub3.pmid: 27577677 PubMed
Bhupathiraju SN, Grodstein M, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause 2018. pmid:30562320 PubMed
Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016 Oct 12;10:CD008536. Epub ahead of print. pmid: 27733017 PubMed
Islam RM, Bell RJ, Green S et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol 2019; 25: S2213-8587. pmid:31353194 PubMed
Johansen N, Lindén Hirschberg A, Moen MH. The role of testosterone in menopausal hormone treatment. What is the evidence? Acta Obstet Gynecol Scand. 2020 Aug;99(8):966-969. Epub 2020 Mar 2. PMID: 32027015.
Davis SR, Moreau M, Kroll R et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008; 359: 2005-17. PMID: 18987368 PubMed
Davis SR, Baber R, Panay N et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric 2019. epub 2:1-6. pmid:31474158 PubMed
Elraiyah T, Sonbol MB, Wang Z et al. Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014; 99(10): 3543-50. pmid:25279572 PubMed
Gaudard AIS, Silva de Souza S et al. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No.: CD010407 pmid: 27479272 PubMed
MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. The Cochrane Library, Jan 21, 2009. pmid: 15495039 PubMed
Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017 Dec 12;318(22):2234-2249. doi: 10.1001/jama.2017.16952. (Systematic Review) PMID: 29234813 PubMed
Renoux C, Dellàniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010; 340: c2519. pmid: 20525678 PubMed
Lokkegaard E, Nielsen LH, Keiding N. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke. 2017; 48: 2266-9. PMID: 28626058 PubMed
Haimov-Kochman R, Barak-Glantz E, Arbel R et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause. 2006 May-Jun;13(3):370-6. PMID: 16735933.
Shams T, Firwana B, Habib F, et al. SSRIs for Hot Flashes: A systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2013 Jul 26 PMID: 23888328 PubMed
Sarri G, Pedder H, Dias S, Guo Y1, Lumsden MA. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute of Health and Care Excellence guideline on menopause. BJOG 2017. pmid:28276200 PubMed
Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011;12:570-7. PubMed
Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes. Systematic review and meta-analysis. JAMA 2006; 295: 2057-71. pmid: 16670414 PubMed
Leon-Ferre RA, Novotny PJ, Wolfe EG et al. Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectr. 2019 Oct 21;4(1):pkz088. PMID: 32337497 PubMed
O'Connor KA, Ferrel R, Brindle E, et al. Progesterone and ovulation across stages of the transition to menopause. Menopause 2009; 16: 1178-87. pmid: 19568209 PubMed
Widnes SF, Myklebust ÅJ. Forlenget bruk av hormonspiral hos premenopausale kvinner. Utposten 2016; 2: 46-7. www.utposten.no
Norsk Endokrinologisk Forening. Osteoporose. I Nasjonal veileder i endokrinologi. Publisert 26.02.2020. Siden lest 20.10.2020. www.prosedyrer.no
Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women study. Lancet 2003; 362: 419-27. PubMed
Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: A systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157: 1-10. pmid: 22786830 PubMed
Mosekilde L, Beck-Nielsen H, Sørensen OH et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181-93. pmid:11063900 PubMed
Pinkerton JAV, Aguirre FS, Blake J et al. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017 Jul 1;24(7):728-753. PMID: 28650869 PubMed
Rossouw JE, Anderson GL, Prentice RLet al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33. PMID: 12117397.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350:1047-59. PubMed
Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women`s Health Initiative observational study. J Natl Cancer Inst 2013; 105: 526-35. pmid: 23543779 PubMed
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the QResearch and CPRD databases. BMJ 2020. PMID: 33115755 PubMed
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA 2017; 318: 927-38. pmid:28898378 PubMed
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019. pmid:31474332 PubMed
Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015. pmid: 25684585 PubMed
Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's health initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374: 1243-51. PubMed
Schierbeck LL, Rejnmark L, Tofteng CL et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012. pmid:23048011 PubMed
Anderson GL, Limacher M, Assaf AR et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701-12. PMID: 15082697. PubMed
Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormon therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30: 340-5. PubMed
Liu B, Beral V, Balkwill A et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337: a386. PubMed
Moro E, Degli Esposti E, Borghese G et al. The Impact of Hormonal Replacement Treatment in Postmenopausal Women with Uterine Fibroids: A State-of-the-Art Review of the Literature. Medicina (Kaunas). 2019 Aug 30;55(9):549. PMID: 31480288 PubMed
Moen MH, Rees M, Brincat M et al. European Menopause and Andropause Society. EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas. 2010 Sep;67(1):94-7. PMID: 20627430. PubMed
Attarian H, Hachul H, Guttuso T, Phillips B. Treatment of chronic insomnia disorder in menopause: evaluation of literature. Menopause 2015; 22: 674-84. pmid:25349958 PubMed
Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD003122. DOI: 10.1002/14651858.CD003122.pub2 DOI
Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F et al. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ 2019; 364: I665. pmid:30842086 PubMed
Holmberg L, Iversen OE, Rudenstam CM, et al. HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-82. PubMed
Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis . BMJ 2008; 336: 1227-31. PubMed
Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 49-57. PubMed
Lund KS, Siersma V, Brodersen J, Waldorff FB. Efficacy of a standardised acupuncture approach for women with bothersome menopausal symptoms: a pragmatic randomised study in primary care (the ACOM study). BMJ Open 2019; 9: e023637. pmid:30782712 PubMed
Dodin S, Blanchet C, Marc I et al. Acupuncture for menopausal hot flushes. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD007410. DOI: 10.1002/14651858.CD007410.pub2 DOI
Guthrie KA, LaCroix AZ, Ensrud KE, et al. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstet Gynecol 2015; 126: 413-22. pmid: 26241433 PubMed
Sternfeld B et al. Efficacy of exercise for menopausal symptoms: A randomized controlled trial. Menopause 2014; 21:330. pmid: 23899828 PubMed
Daley A, Thomas A, Roalfe A, et al. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG. 2014 PMID: 25516405 PubMed
Newton KM, et al. Efficacy of yoga for vasomotor symptoms: A randomized controlled trial. Menopause 2014; 21:339. pmid: 24045673 PubMed
Cohen LS, et al. Efficacy of omega-3 for vasomotor symptoms treatment: A randomized controlled trial. Menopause 2014; 21:347. pmid: 23982113 PubMed
Zhu X, Liew Y, Liu ZL. Chinese herbal medicine for menopausal symptoms. Cochrane Database Syst Rev. 2016 Mar 15;3: pmid: 26976671 PubMed
Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD001395. pmid:24323914 PubMed
Franco OH, Chowdhury R, Troup J, et al. Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis. JAMA. 2016; 315: 2554-63. pmid: 27327802 PubMed
Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD007244. pmid: 22972105 PubMed
Honigberg MC, Zekavat SM, Aragam K, et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA 2019. doi:10.1001/jama.2019.19191 DOI
Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108: 41-8. PubMed

Meld deg på nyhetsbrev

Er du helsepersonell?

Ved å oppgi dette kan du få bedre tilpasset innhold om du har formell helsefaglig kompetanse

Annonsørinnhold

Annonsørinnhold fra Sanofi

Atopisk eksem: Ikke alle barn «vokser det av seg»

Over 40 prosent av barn med atopisk eksem har med seg sykdommen inn i ungdommen og voksenlivet. Hva bør du som forelder være oppmerksom på?

MAT-NO-2200196 v1.0 04/2022

Annonsørinnhold fra Navamedic

Ernæringsfysiologens råd ved irritabel tarm

Setter mageplager begrensninger for hva du gjør og hvordan du lever livet ditt? Dessverre er det mange nordmenn som har det slik, men det finnes hjelp.

Annonsørinnhold fra Helsedirektoratet

Å få hverdagen tilbake etter covid-19

Intensivsykepleieren Linn Therese Braaten Lien (32) fikk hjelp for senfølger etter covid-19 hos Kompani Covid i Bergen.

Mest lest i dag

Barn

Overgangsalderen

Hopp til innhold

Hva er overgangsalderen?

Er du helsepersonell?

Annonsørinnhold

Atopisk eksem: Ikke alle barn «vokser det av seg»

Ernæringsfysiologens råd ved irritabel tarm

Å få hverdagen tilbake etter covid-19

Mest lest i dag

Hånd-, fot- og munnsykdom

Symptomer på infeksjon med coronavirus

Covid-19 - varighet

Informasjon

Hold deg oppdatert

Overgangsalderen

Hopp til innhold

Hva er overgangsalderen?

Er du helsepersonell?

Andre leste også dette

Annonsørinnhold

Mest lest i dag